Review: taking Namenda and Lunesta together


Summary

Drug interactions are reported among people who take Namenda and Lunesta together. This review analyzes the effectiveness and drug interactions between Namenda and Lunesta. It is created by eHealthMe based on reports of 89 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Namenda and Lunesta >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Namenda

Namenda has active ingredients of memantine hydrochloride. It is often used in dementia alzheimer's type. (latest outcomes from Namenda 7,861 users)

Lunesta

Lunesta has active ingredients of eszopiclone. It is often used in insomnia. (latest outcomes from Lunesta 17,192 users)

On Aug, 28, 2016

89 people who take Namenda, Lunesta are studied.


Number of reports submitted per year:

Namenda and Lunesta drug interactions.

Drug effectiveness over time:

Namenda:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Lunesta:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 3 people)
  • 2 - 5 years: 50.0% - (1 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Namenda:
  • female: 33.0% - (1 of 3 people)
  • male: 0.0% - (0 of 3 people)
Lunesta:
  • female: 0.0% - (0 of 3 people)
  • male: 33.0% - (1 of 3 people)

Drug effectiveness by age:

Namenda:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 1 people)
  • 60+: 33.0% - (1 of 3 people)
Lunesta:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 1 people)
  • 60+: 33.0% - (1 of 3 people)

Most common drug interactions over time *:

< 1 month:
  • pneumonia
  • aggression
  • confusional state
  • death
  • depression
  • dyspnoea
  • restlessness
  • unresponsive to stimuli
  • abdominal pain
  • agitation
1 - 6 months:
  • pneumonia
  • angiopathy
  • atrioventricular block second degree
  • blood pressure fluctuation
  • bundle branch block right
  • cardiac failure
  • confusional state
  • dyspnoea
  • hypokalaemia
  • muscle rigidity
6 - 12 months:
  • choking
  • insomnia
  • pleurisy
  • pneumonia
  • skeletal injury
1 - 2 years:
  • discomfort
  • hair loss
  • hepatic enzyme increased
  • musculoskeletal chest pain
  • gastrointestinal hypomotility
  • gastroparesis
  • blood creatine phosphokinase increased
2 - 5 years:
  • hair loss
10+ years:
  • gastrointestinal hypomotility
  • gastroparesis
  • choking
  • pleurisy
  • pneumonia
  • skeletal injury
not specified:
  • insomnia
  • confusional state
  • malaise
  • convulsion
  • dehydration
  • fall
  • speech disorder
  • urinary tract infection
  • catatonia
  • depressed level of consciousness

Most common drug interactions by gender *:

female:
  • confusional state
  • convulsion
  • catatonia
  • depressed level of consciousness
  • fall
  • feeling abnormal
  • general physical health deterioration
  • hypertensive crisis
  • infection
  • pneumonia
male:
  • insomnia
  • malaise
  • aggression
  • hypotension
  • dyspnoea
  • pneumonia
  • cataract
  • confusional state
  • dehydration
  • dementia

Most common drug interactions by age *:

0-1:
  • blood cholesterol increased
  • blood triglycerides increased
  • hyperprolactinaemia
  • leiomyoma
  • obesity
  • osteoarthritis
  • patellofemoral pain syndrome
  • stress fracture
  • type 2 diabetes mellitus
30-39:
  • acanthosis
  • arthralgia
  • asthma
  • blood cholesterol increased
  • blood triglycerides increased
  • chest pain
  • constipation
  • convulsion
  • dyspnoea
  • fracture
40-49:
  • gastrointestinal hypomotility
  • gastroparesis
  • blood creatine phosphokinase increased
  • discomfort
  • hepatic enzyme increased
  • musculoskeletal chest pain
50-59:
  • atrial fibrillation
  • cardiac failure congestive
  • diastolic dysfunction
  • intracardiac thrombus
  • left ventricular hypertrophy
  • pneumonia
  • pulmonary hypertension
  • respiratory arrest
  • upper respiratory tract infection
  • cyanosis
60+:
  • confusional state
  • insomnia
  • convulsion
  • dehydration
  • fall
  • malaise
  • aggression
  • catatonia
  • depressed level of consciousness
  • feeling abnormal

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Namenda and Lunesta?

Can you answer these questions?

More questions for: Namenda, Lunesta

You may be interested in these reviews

More reviews for: Namenda, Lunesta

On eHealthMe, Namenda (memantine hydrochloride) is often used to treat dementia alzheimer's type. Lunesta (eszopiclone) is often used to treat insomnia. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.